Pfizer "terminates" Lipitor OTC switch in US

28 July 2015 - Deborah Wilkes


Pfizer has "terminated" its programme to switch the cholesterol-lowering drug Lipitor (atorvastatin) from prescription-to-OTC status in the US. Chief executive officer Ian Read said the company "continues to evaluate other products for potential prescription-to-OTC switches".

Click tags below for more information on topics:

FDA Statins

Annual Subscription Holder?

Sign in to continue reading.

Sign In

Back to Industry News

Share this page: